montelukast (Singulair)

Subscribe to Selected New Research on montelukast

643 relevant articles (166 outcomes, 221 trials/studies) found for this Drug

Description: a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source

Also Known As:

Singulair; Cahill May Roberts brand of montelukast sodium; MK 0476; MK-0476; Merck Frosst brand of montelukast sodium; Merck Sharp & Dohme brand of montelukast sodium; Merck brand of montelukast sodium; montelukast sodium; sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Quinolines: 58

montelukast: 643

Experts

1.	Reiss, Theodore F: 13 articles (10/2008 - 01/2002)
2.	Philip, George: 8 articles (05/2007 - 06/2002)
3.	Malice, Marie-Pierre: 7 articles (10/2008 - 06/2002)
4.	Dass, S Balachandra: 7 articles (10/2008 - 10/2003)
5.	Kuna, Piotr: 7 articles (01/2007 - 01/2002)
6.	Stelmach, Iwona: 7 articles (10/2005 - 02/2002)
7.	Lipworth, B J: 7 articles (08/2004 - 09/2000)
8.	Reiss, T F: 7 articles (12/2003 - 05/2000)
9.	Edelman, Jonathan M: 6 articles (04/2007 - 12/2002)
10.	Bisgaard, Hans: 5 articles (10/2008 - 04/2003)

Related Diseases

1.	Asthma (Bronchial Asthma) 11/01/2006 - "Following treatment with 10mg montelukast 86.5% (n=4547) of patients reported a strong or marked improvement in day-time asthma symptoms and 88.5% (n=4367) reported improvement in night-time symptoms" 01/01/2001 - "Montelukast, a new leukotriene modifier, has several benefits in the treatment of asthma in adults and children including improved relief of asthma symptoms, rapid onset, a safety profile comparable with placebo, and oral, once-daily dosing means excellent adherence." 04/01/2008 - "By the end of the study, which consisted of montelukast treatment, a significant improvement over baseline was noted in asthma symptoms and severity, as well as in treatment compliance" 12/01/1999 - "In placebo-controlled clinical trials, montelukast significantly improved pulmonary lung function (as measured by forced expiratory volume in 1 sec), significantly reduced beta2-agonist use, and significantly improved patient-reported end points in adults and children (> or =6 y) with chronic asthma" 01/01/2006 - "Compared with placebo, treatment with montelukast resulted in a significant improvement from baseline in the daytime asthma symptom score (-0.54 vs -0.34; P = .002) and in beta-agonist use, nighttime symptoms, and peak expiratory flow rates" Get all the results and reference details, order at left...
2.	Rhinitis 02/01/2003 - "The treatment effect of montelukast was significantly greater (P < 0.05), relative to placebo, for all secondary endpoints, including nighttime symptoms and daytime eye symptoms, patient and physician global evaluations of allergic rhinitis, and rhinoconjunctivitis quality of life" 12/01/2005 - "Montelukast treatment also improved global evaluations of allergic rhinitis by patients and Rhinoconjunctivitis Quality of Life Questionnaire scores: differences vs the placebo group were -0.15 (95% CI, -0.27 to -0.04; P < .01) and -0.15 (95% CI, -0.24 to -0.06; P < .001), respectively" 06/01/2006 - "Recent studies have demonstrated that montelukast is also effective in treating daytime and nighttime allergic rhinitis (AR) symptoms in asthmatic patients" 03/01/2004 - "Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies." 06/01/2007 - "Montelukast in the management of allergic rhinitis." Get all the results and reference details, order at left...
3.	Seasonal Allergic Rhinitis (Hay Fever) 12/01/2006 - "CONCLUSION: Montelukast treatment provided significant improvement in symptoms and peripheral eosinophil counts of school-age children with seasonal allergic rhinitis; however, it did not show a significant effect on eNO levels." 03/01/2004 - "CONCLUSIONS: Montelukast significantly improved daytime nasal symptoms score in patients with seasonal allergic rhinitis, and the effect was greater in patients exposed to higher pollen levels." 09/01/2008 - "CONCLUSIONS: Both montelukast 5 mg and 10 mg doses show clinically meaningful efficacy for the treatment of patients with seasonal allergic rhinitis and the safety profiles of those are comparable to that of the placebo." 11/01/2005 - "Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis." 01/01/2005 - "Montelukast has shown efficacy for seasonal allergic rhinitis (SAR); however, onset of action for SAR has not been presented" Get all the results and reference details, order at left...
4.	Inflammation 07/01/2006 - "Other therapies, including montelukast, partial dietary elimination, and bouginage have reduced symptoms without affecting mucosal inflammation" 05/01/2006 - "Montelukast reduced the severity of airway inflammation and the number of eosinophils in asthmatic guinea pigs" 11/01/2002 - "In a number of clinical experiments, montelukast not only improved asthmatic symptoms and respiratory indices, but also inhibited airway inflammation and exercise-induced bronchoconstriction" 08/01/2003 - "In this study, we hypothesized that steroid-treated children exhibit a decrease in bronchial inflammation in induced sputum under additional treatment with montelukast" 03/01/2002 - "This study shows that triamcinolon, montelukast contribute to inhibition of allergic inflammation by decreasing eosinophil blood counts and ECP" Get all the results and reference details, order at left...
5.	Urticaria (Hives) 05/01/2006 - "DATA SOURCES: MEDLINE (1966-March 2006) and International Pharmaceutical Abstracts (1970-October 2005) were searched to find clinical trial publications that addressed the use of montelukast in urticaria" 05/01/2006 - "OBJECTIVE: To review clinical trial data to determine the benefits of using montelukast alone or as combination therapy in the treatment of urticaria" 05/01/2006 - "Montelukast treatment of urticaria." 06/01/2004 - "In cases of generalized urticaria in asthmatic patients undergoing montelukast therapy, physicians should be aware of a potential adverse reaction to this drug." 06/01/2004 - "OBJECTIVE: To report a case of generalized urticaria induced by montelukast treatment" Get all the results and reference details, order at left...
116 Diseases and 643 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	fluticasone (Cutivate)
2.	salmeterol (Serevent)
3.	Leukotriene Receptors (Leukotriene Receptor)
4.	Adrenal Cortex Hormones (Corticosteroids)
5.	Budesonide (Pulmicort)
6.	leukotriene D4 receptor (cysteinyl leukotriene receptor)
7.	Loratadine (Alavert)
8.	Aspirin (Acetylsalicylic Acid)
9.	Cetirizine (Zyrtec)
10.	Leukotriene Antagonists (Leukotriene Receptor Antagonists)
172 Drugs and Important Bio-Agents and 469 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Nebulizers and Vaporizers (Inhaler)
3.	Respiratory Therapy (Therapy, Respiratory)
4.	Emergency Treatment
5.	Drug Therapy (Chemotherapy)
10 Therapies and Procedures and 22 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>